Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213572605> ?p ?o ?g. }
- W3213572605 endingPage "5657" @default.
- W3213572605 startingPage "5657" @default.
- W3213572605 abstract "There has been speculation that IOP-lowering medication, which increases aqueous humor outflow, increases the risk of metastatic uveal melanoma (UM). This hypothesis has not been studied previously but is relevant for UM patients who use IOP-lowering medication. The aim of the current study is to assess the association between the use of intraocular pressure (IOP)-lowering medication and the risk of metastatic UM, and mortality.A retrospective cohort study, in which patients from the Rotterdam Ocular Melanoma Study were included from 1986 onwards. Medical records were evaluated for use of IOP-lowering medication at baseline (i.e., before diagnosis). For each IOP-lowering medication, we divided patients into two groups for comparison (e.g., patients with alpha2-agonist use and patients without alpha2-agonist use). All patients underwent regular ophthalmic examinations and routine screening for metastasis. Survival analyses were initiated to compare groups in each IOP-lowering medication group. In addition, secondary analyses were performed to examine the association between IOP and the development of metastatic UM, and mortality.A total of 707 patients were included of whom 13 patients used prostaglandin or pilocarpine at baseline. For alpha2-agonist, beta-blocker, carbonic anhydrase inhibitor, and oral IOP-lowering medication these were 4, 14, 11, and 12 patients, respectively. The risk of metastatic UM (choroid and ciliary body melanoma) among the prostaglandin/pilocarpine users was significantly higher than controls (HR [95% CI]: 4.840 [1.452-16.133]). Mortality did not differ significantly among the IOP-lowering medications groups, except for the prostaglandin or pilocarpine group (HR [95% CI]: 7.528 [1.836-30.867]). If we combined all IOP-lowering medication that increase aqueous humor outflow, the risk (HR [95% CI]) of metastatic UM and mortality was 6.344 (1.615-24.918) and 9.743 (2.475-38.353), respectively. There was an association between IOP and mortality, but not for the onset of metastatic UM.The use of topical prostaglandin or pilocarpine may increase the risk of metastatic UM and mortality compared to patients without prostaglandin or pilocarpine use. Therefore, use of IOP-lowering medication which increases aqueous humor outflow, should be avoided in patients with (presumed) UM." @default.
- W3213572605 created "2021-11-22" @default.
- W3213572605 creator A5012019655 @default.
- W3213572605 creator A5013942569 @default.
- W3213572605 creator A5031905985 @default.
- W3213572605 creator A5040057938 @default.
- W3213572605 creator A5048549381 @default.
- W3213572605 creator A5048607719 @default.
- W3213572605 creator A5065668495 @default.
- W3213572605 creator A5071455253 @default.
- W3213572605 date "2021-11-12" @default.
- W3213572605 modified "2023-09-25" @default.
- W3213572605 title "The Effect of Intraocular Pressure-Lowering Medication on Metastatic Uveal Melanomas" @default.
- W3213572605 cites W123314342 @default.
- W3213572605 cites W1500363075 @default.
- W3213572605 cites W1542223057 @default.
- W3213572605 cites W1970127416 @default.
- W3213572605 cites W1981793422 @default.
- W3213572605 cites W2002578259 @default.
- W3213572605 cites W2034082998 @default.
- W3213572605 cites W2040607067 @default.
- W3213572605 cites W2050715409 @default.
- W3213572605 cites W2050970383 @default.
- W3213572605 cites W2052638246 @default.
- W3213572605 cites W2055835855 @default.
- W3213572605 cites W2059734400 @default.
- W3213572605 cites W2067354849 @default.
- W3213572605 cites W2072837230 @default.
- W3213572605 cites W2090110993 @default.
- W3213572605 cites W2094037235 @default.
- W3213572605 cites W2099523789 @default.
- W3213572605 cites W2101033555 @default.
- W3213572605 cites W2107109105 @default.
- W3213572605 cites W2126279698 @default.
- W3213572605 cites W2135166720 @default.
- W3213572605 cites W2136802909 @default.
- W3213572605 cites W2143878396 @default.
- W3213572605 cites W2151347570 @default.
- W3213572605 cites W2166771927 @default.
- W3213572605 cites W2281707699 @default.
- W3213572605 cites W2301440856 @default.
- W3213572605 cites W2338228645 @default.
- W3213572605 cites W2461878722 @default.
- W3213572605 cites W2729341911 @default.
- W3213572605 cites W2783866215 @default.
- W3213572605 cites W2800660348 @default.
- W3213572605 cites W2903666949 @default.
- W3213572605 cites W2914299580 @default.
- W3213572605 cites W2962490452 @default.
- W3213572605 cites W2979420081 @default.
- W3213572605 cites W3122714556 @default.
- W3213572605 cites W84625781 @default.
- W3213572605 doi "https://doi.org/10.3390/cancers13225657" @default.
- W3213572605 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8616129" @default.
- W3213572605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34830810" @default.
- W3213572605 hasPublicationYear "2021" @default.
- W3213572605 type Work @default.
- W3213572605 sameAs 3213572605 @default.
- W3213572605 citedByCount "0" @default.
- W3213572605 crossrefType "journal-article" @default.
- W3213572605 hasAuthorship W3213572605A5012019655 @default.
- W3213572605 hasAuthorship W3213572605A5013942569 @default.
- W3213572605 hasAuthorship W3213572605A5031905985 @default.
- W3213572605 hasAuthorship W3213572605A5040057938 @default.
- W3213572605 hasAuthorship W3213572605A5048549381 @default.
- W3213572605 hasAuthorship W3213572605A5048607719 @default.
- W3213572605 hasAuthorship W3213572605A5065668495 @default.
- W3213572605 hasAuthorship W3213572605A5071455253 @default.
- W3213572605 hasBestOaLocation W32135726051 @default.
- W3213572605 hasConcept C118487528 @default.
- W3213572605 hasConcept C118552586 @default.
- W3213572605 hasConcept C120665830 @default.
- W3213572605 hasConcept C121332964 @default.
- W3213572605 hasConcept C126322002 @default.
- W3213572605 hasConcept C167135981 @default.
- W3213572605 hasConcept C2776694393 @default.
- W3213572605 hasConcept C2777093970 @default.
- W3213572605 hasConcept C2777204577 @default.
- W3213572605 hasConcept C2778186239 @default.
- W3213572605 hasConcept C2781092963 @default.
- W3213572605 hasConcept C71924100 @default.
- W3213572605 hasConceptScore W3213572605C118487528 @default.
- W3213572605 hasConceptScore W3213572605C118552586 @default.
- W3213572605 hasConceptScore W3213572605C120665830 @default.
- W3213572605 hasConceptScore W3213572605C121332964 @default.
- W3213572605 hasConceptScore W3213572605C126322002 @default.
- W3213572605 hasConceptScore W3213572605C167135981 @default.
- W3213572605 hasConceptScore W3213572605C2776694393 @default.
- W3213572605 hasConceptScore W3213572605C2777093970 @default.
- W3213572605 hasConceptScore W3213572605C2777204577 @default.
- W3213572605 hasConceptScore W3213572605C2778186239 @default.
- W3213572605 hasConceptScore W3213572605C2781092963 @default.
- W3213572605 hasConceptScore W3213572605C71924100 @default.
- W3213572605 hasIssue "22" @default.
- W3213572605 hasLocation W32135726051 @default.
- W3213572605 hasLocation W32135726052 @default.
- W3213572605 hasLocation W32135726053 @default.
- W3213572605 hasLocation W32135726054 @default.